The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trialParminder K. Judge, William G. Herrington, Masaomi Nangaku et al.|Nephrology Dialysis Transplantation|2024Cited by 66
WCN24-1550 ALDOSTERONE SYNTHASE INHIBITION WITH OR WITHOUT BACKGROUND SODIUM GLUCOSE COTRANSPORTER 2 INHIBITION IN CKD: A PHASE II CLINICAL TRIALKatherine R. Tuttle, Peter Rossing, Sibylle J. Hauske et al.|Kidney International Reports|2024Cited by 2
Cumulative Effects of Aldosterone Synthase and SGLT2 Inhibition on Albuminuria in People with CKDPeter Rossing, Katherine R. Tuttle, Sibylle J. Hauske et al.|Journal of the American Society of Nephrology|2024Cited by 1
WCN25-2620 CUMULATIVE EFFECTS OF THE ALDOSTERONE SYNTHASE INHIBITOR VICADROSTAT COMBINED WITH EMPAGLIFLOZIN ON ALBUMINURIA IN PEOPLE WITH CKDPeter Rossing, Katherine R. Tuttle, Sibylle J. Hauske et al.|Kidney International Reports|2025Cited by 1
#1418 Phase II dose-selection, randomised, controlled trial of ASi BI 690517 with and without EMPA in CKD: subgroup analysis by T2D statusDick de Zeeuw, Peter Rossing, Sibylle J. Hauske et al.|Nephrology Dialysis Transplantation|2024Cited by 1